Kataldi (Chlortalidone)

Chlortalidone blocks the sodium‑chloride cotransporter in the distal convoluted tubule of the kidney. This inhibition reduces reabsorption of sodium and chloride, leading to increased excretion of sodium, water, and potassium, which lowers blood volume and peripheral resistance, thereby decreasing blood pressure.

The appropriate dose of Kataldi is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and renal function. Dosage adjustments are made to achieve optimal blood‑pressure control while minimizing side effects.

Safety data for chlortalidone in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Kataldi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kataldi (chlortalidone) is a thiazide‑like diuretic, often considered more potent and longer‑acting than hydrochlorothiazide. It provides effective blood‑pressure reduction and fluid removal, but may have a higher incidence of electrolyte disturbances, requiring closer monitoring.

Kataldi should be stored at room temperature, below 25 °C, in its original container. Keep the tablets away from moisture, heat, and direct sunlight to maintain stability and potency.

Kataldi is taken orally, usually with a full glass of water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort. Follow the prescribing clinician’s instructions regarding timing and frequency.

The most serious risks include severe electrolyte imbalances such as hyponatremia or hypokalemia, acute kidney injury, and rare but serious reactions like pancreatitis or severe allergic responses. Prompt medical attention is required if symptoms of these conditions appear.

Kataldi is contraindicated in patients with anuria, severe renal impairment, known hypersensitivity to chlortalidone or other sulfonamide drugs, and in individuals with severe hepatic dysfunction. Clinicians should evaluate each patient’s medical history before prescribing.